Table 24Beta-blocker medication intervention versus placebo: results

Author, YearComparison GroupsTraumatic Symptom OutcomesMental Health OutcomesPhysical Health OutcomesOther Outcomes
Nugent, et al., 201057G1: Propanolol liquid medication (20 mg/5 mL) at 2.5 mg/kg dosing split twice daily with a 5-day taper and maximum daily dosage of 40 mg twice daily for a total of 10 days.
G2: Liquid placebo twice daily for 10 days.
No between-group difference in changes in difference in proportion of those with PTSD diagnosis or changes in PTSD symptoms (CAPS-CA; range not reported)

Diagnosis:
No data reported for PTSD diagnosis other than x2<1; p=NS for G1 vs. G2 at post-treatment

Symptoms:
No means reported.

Between-group differences at followup not reported. Intent-to-treat linear regression predicting PTSD symptoms at post-treatment, adjusted for sex, age, and prior trauma PTSD severity, showed treatment group OR (95% CI)=1.32 (0.84, 2.08) (calculated*)
NRNo between-group difference in heart rate during or after trauma narrative p=NS.

No other data given
NR

CAPS-CA = Clinician-Administered Posttraumatic Stress Disorder Scale for Children and Adolescents; CI = confidence interval; G= group; kg = kilogram; mg = milligram; mL = milliliter; NR = not reported; NS = not sufficient; OR = odds ratio; PTSD = post-traumatic stress disorder

*

Calculation is an estimation based on reported unstandardized coefficient and standard error and calculated standard deviation of the treatment group variable, assuming no correlation with other variables in the multivariate model.

Calculation is an estimation based on reported unstandardized coefficient and standard error and calculated standard deviation of the treatment group variable, assuming no correlation with other variables in the multivariate model.

From: Results

Cover of Child and Adolescent Exposure to Trauma
Child and Adolescent Exposure to Trauma: Comparative Effectiveness of Interventions Addressing Trauma Other Than Maltreatment or Family Violence [Internet].
Comparative Effectiveness Reviews, No. 107.
Forman-Hoffman V, Knauer S, McKeeman J, et al.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.